Hardman Johnston Global Advisors LLC Has $54.28 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Hardman Johnston Global Advisors LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 229,055 shares of the medical research company’s stock after purchasing an additional 1,360 shares during the quarter. IQVIA makes up about 2.1% of Hardman Johnston Global Advisors LLC’s holdings, making the stock its 15th biggest position. Hardman Johnston Global Advisors LLC owned approximately 0.13% of IQVIA worth $54,279,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Versant Capital Management Inc grew its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA in the 2nd quarter worth about $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA during the third quarter worth approximately $28,000. Itau Unibanco Holding S.A. acquired a new stake in IQVIA during the 2nd quarter valued at $29,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the second quarter valued at $32,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. Evercore ISI reduced their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Truist Financial dropped their price objective on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday. Argus upgraded IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, Barclays cut their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $259.13.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $212.96 on Wednesday. The company has a fifty day moving average price of $232.84 and a 200 day moving average price of $229.54. The firm has a market cap of $38.65 billion, a PE ratio of 27.95, a PEG ratio of 2.07 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 1-year low of $190.20 and a 1-year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.